The pathogenesis of the progressive loss of dopaminergic neurons in the substantia nigra (SN), characteristic of Parkinson's disease (PD) has not yet been revealed. One of the theories'-3 is that PD patients have a defective antioxidant system, leading to an increased formation of highly reactive free oxygen radicals (O). These are able to react with, for example, poly-unsaturated fatty acids of the cell membranes, thereby causing cells to lyse and die. The free radical formation is a result of monoamineoxidase activity4 in the SN, and of the oxidation of dopamine via 6-hydroxydopamine Studies on erythrocytes (rbc) by Poirrier and Barbeau'3 did not find any reduction in rbc-GSH, rbc-GSH-px, superoxide dismutase and catalase activity, while a study by Kilinc et al'4 concluded that the rbc-GSH-px activity was significantly reduced in Parkinsonian patients compared with controls. Thus it is still undecided whether the reduced antioxidant activity found in the SN in PD patients is part of a general aberration or is of local origin.
The main problem in the management of PD is the long-term complications of levodopa treatment, known as the late Parkinsonian syndrome.'5 16 It consists of highly disabling fluctuations in motor performance and occurrence of abnormal, involuntary movements.
Previous studies on the antioxidant system in PD have not differentiated between early and advanced cases. The possibility that levodopa therapy, via 6-OHDA, might enhance the destruction of the SN (4) makes it relevant to study the possible correlation between the progression of PD and the antioxidant system.
The aim of this study was to determine whether there is a difference in the antioxidant activity, measured by rbc-GSH-px activity and selenium in plasma and erythrocytes, between Parkinsonian patients in the early stages of the disease and patients with advanced disease. 3). When omitting those taking selenium supplementation, however, there was no significant difference between the two groups. Nor did rbc-selenium show any significant differences between the two groups ( fig 1) and in plasma-selenium by 25-9 per cent (p = 0-011) (table 3, fig 1) , while the 112 per cent rise in rbc-selenium in this group from 184 ug/l cells to 205 ig/l cells (table 4) was not significant(p = 0-48). Thethreeoldestpatients in group A, who took supplementary selenium, showed very high levels in rbc-GSH-px, indicating that the stage of disease may be of more importance than age (fig 2) .
As expected a significant correlation between levels of rbc-GSH-px and plasma-selenium was found in group A (r = 0-64; p < 0.0005).21 22 This did not apply to group B (r = 0-25; p = 0-22). For the patients without selenium supplementation, no significant correlation between rbc-GSH-px and age was found in either group A or B (fig 1) , but a significant correlation between rbc-GSH-px and duration of disease was found within the two individual groups (fig 2) .
Erythrocyte-GSH-px shows no significant correlation to the UPDRS-score in group A (p = 0 66) or in group B (p = 0 20).
A significant correlation between plasmaselenium and age was shown in group A in patients without selenium supplementation but not between plasma-selenium and duration of disease (table 5). The opposite was seen in group B in which a significant correlation between plasma-selenium and duration of disease was seen but not between plasmaselenium and age. As shown in table 6, rbcselenium has no significant correlation with either age or duration of disease in group A, but in group B the results are the same as those for plasma-selenium.
The interview on food habits revealed that there was no difference between the two groups on the estimated energy intake, quality of food or adequacy of nutritional elements that could influence the GSH-px level. The only exception was the selenium supplementation used by 15 of the patients. There was no difference between the sexes concerning any of the parameters.
Discussion
The aim of this study was to investigate whether there is a difference in antioxidant activity between PD patients at the early stage of their disease and those suffering from advanced PD. We believe that this aim has been fulfilled.
Parkinsonian patients in the late phase of the disease have a lower antioxidant activity as expressed by a significantly decreased rbc-GSH-px activity. This decrease could not be explained by differences in dietary habits, energy intake or lack of trace element supplementation. In the single groups A and B rbc-GSH-px does not decrease with age, but the correlation with duration of disease was significant for those patients without selenium supplementation. Those patients who had the longest duration of the disease and advanced symptoms also had the lowest rbc-GSH-px and thus the lowest antioxidant activity. The study cannot tell whether the reduction in rbc-GSH-px is a part of the pathogenesis or a result of the disease or the drug treatment. A clue is provided by fig 2 suggesting that the reduction in rbc-GSH-px is a result of the disease or drug treatment due to the steady decline during the years of disease. All patients without selenium supplementation. r = correlation coefficient. p = probability. 
